Study S001438

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects.

ClinicalTrials.gov record

Registration

Registration: NCT02235961
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 163
Start: 2014-09-04
Primary completion: 2016-07-06
Lead sponsor: Novo Nordisk A/S
Conditions: Metabolism and Nutrition Disorder; Obesity
Interventions: DRUG:NNC9204-0530; DRUG:liraglutide; DRUG:placebo
Results posted: FALSE
Secondary identifiers: REGISTRY:U1111-1151-0761

Registered primary outcomes

Number of treatment emergent adverse events recorded [From time of dosing of NNC9204-0530 (Day 1) until completion of the follow-up visit (Day 21-27)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.